873936-98-2

Usage

Uses

Used in Agricultural Industry:
2,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide is used as a pesticide and herbicide for controlling the growth of unwanted plants. It functions by inhibiting the activity of the enzyme acetohydroxy acid synthase, which is crucial for the biosynthesis of branched-chain amino acids in plants. This inhibition disrupts protein synthesis and growth, ultimately leading to the death of the targeted plants.
Used in Pharmaceutical Research:
2,6-Dichloro-N-methoxy-N-methylpyridine-3-carboxamide is also being investigated for its potential use in the treatment of cancer. It has shown the ability to inhibit the growth of tumor cells in some studies, suggesting that it could be a candidate for further research into its mechanism of action and possible therapeutic applications in oncology. However, more extensive research is required to fully understand its impact and to develop it as a viable treatment option.

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 58584-83-1 2,6-dichloronicotinoyl chloride 

Downstream Products

• 412018-50-9 1-(4,6-dichloropyridin-3-yl)ethan-1-one 
• 1375708-67-0 1-(2,6-dichloro-pyridin-3-yl)-ethanol 
• 166525-47-9 1-(2,6-dichloropyridin-3-yl)propan-1-one 
• 1256826-72-8 6-chloro-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 873937-00-9 (2,6-Dichloro-pyridin-3-yl)-(2-methoxy-phenyl)-methanone 

Relevant academic research and scientific papers

Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer

Selective cyclooxygenase (COX)-2 inhibitors have been extensively studied for colorectal cancer (CRC) chemoprevention. Celecoxib has been reported to reduce the incidence of colorectal adenomas and CRC but is also associated with an increased risk of cardiovascular events. Here, we report a series of gut-restricted, selective COX-2 inhibitors characterized by high colonic exposure and minimized systemic exposure. By establishing acute ex vivo 18F-FDG uptake attenuation as an efficacy proxy, we identified a subset of analogues that demonstrated statistically significant in vivo dose-dependent inhibition of adenoma progression and survival extension in an APCmin/+ mouse model. However, in vitro-in vivo correlation analysis showed their chemoprotective effects were driven by residual systemic COX-2 inhibition, rationalizing their less than expected efficacies and highlighting the challenges associated with COX-2-mediated CRC disease chemoprevention.

NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS

The invention relates to novel indole and indazole compounds characterized in that the compound has general formula (I), in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicament

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

DIFLUOROMETHYLENE COMPOUND

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases

The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.

2,6-Diaminopyridine derivatives

Novel 2,6-diaminopyridine derivatives of formula wherein R1 and R2 are as defined below, are disclosed. These compounds inhibit cyclin-dependent kinases. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors. Also disclosed are intermediates useful in the preparation of these novel 2,6-diaminopyridine derivatives.